PROSOMNUS, INC.

Highlights ProSomnus, Inc.

Equities

OSAPQ

US50535E1082

Market Closed - OTC Markets Other stock markets 09:30:02 2024-06-21 EDT			5-day change	1st Jan Change
0.01 ^USD	-15.97%		0.00%	-98.98%

05-24	Joint Reorganization Plan and Disclosure Statement Filed by ProSomnus, Inc.	CI
05-20	ProSomnus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ProSomnus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
Prosomnus Contributes Two Scientific Abstracts Accepted for Presentation At the 2024 American Academy of Dental Sleep Medicine Annual Meeting	05-13	CI
ProSomnus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
ProSomnus, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-26	CI
Prosomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea	02-22	CI
ProSomnus, Inc. Severe Indication 510(K) Submission Accepts for Review by the Fda	01-30	CI
ProSomnus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Earnings Flash (OSA) PROSOMNUS SLEEP TECHNOLOGIES Posts Q3 Revenue $7.1M, vs. Street Est of $7.03M	11-09	MT
Prosomnus, Inc. Announces Updated Clinical Trial Data	23-08-23	CI
ProSomnus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
ProSomnus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
ProSomnus, Inc. Announces the Results of a Retrospective Study Demonstrating the Efficacy of Precision Oral Appliance Therapy Compared to Traditional Oat for the Treatment of OSA	23-04-24	CI
ProSomnus Issued US Patent Covering Technology for Precision Sleep Apnea Devices	23-04-05	MT
ProSomnus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
ProSomnus, Inc. Appoints Brian Dow as Chief Financial Officer	23-03-01	CI
ProSomnus, Inc. Provides Revenue Guidance for the Year Ended December 31, 2022	23-02-01	CI
ProSomnus, Inc. Announces Completion of Enrollment in Antwerp University Hospital’s First Line Obstructive Sleep Apnea Treatment Study	22-12-21	CI
ProSomnus, Inc. Enrolls First Participant in Study Evaluating Safety and Efficacy of ProSomnus EVO(TM) in Treating Severe Obstructive Sleep Apnea	22-12-19	CI
ProSomnus, Inc. Announces Medicare Reimbursement for Prosomnus Evo(R) [Ph] Sleep Apnea and Snoring Device	22-12-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer